AVRO News and Press, AVROBIO Inc. From 02/24/20

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the Cowen and Company 40 th Annual Health Care Conference at 4:50 p.m. E...

AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 4,350,000 shares of its common stock. The aggregate gross proceeds to the company from the offering, before deducting underwritin...

Shares of Avrobio (NASDAQ: AVRO) fell as much as 16.4% today after the company announced and priced a public offering of common stock. The small-cap biopharmaceutical company will raise up to $115 million in gross proceeds by selling up to 5 million shares at $23 apiece.  The move wise...

Gainers:  CounterPath (NASDAQ: CPAH ) +32% . More news on: CounterPath Corporation, Genprex, Inc., Happiness Biotech Group Limited, Stocks on the move, , Read more ...

XBiotech (NASDAQ: XBIT )  -26%  on preliminary results of tender offer . More news on: XBiotech Inc., Akorn, Inc., Catalyst Biosciences, Inc., Stocks on the move, , Read more ...

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per share. Gross proceeds from the underwritten public offering will total a...

Gainers: WLL   +7.3% . RRD   +7.1% . RDFN   +5.1% . ASLN   +3.2% . TRIP   +3.1% . More news on: Whiting Petroleum Corporation, R.R. Donnelley & Sons Company, Redfin Corporation, Stocks on the move, , , News on ETFs Read more ...

AVROBIO (NASDAQ: AVRO) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We are raising our PT on AVRO from $28 to $35 following positive clinical data updates yesterday at WORLDSymposium 2020 where we also attended the compa...

Early data trends from first patient dosed in the AVR-RD-04 investigational gene therapy program for cystinosis show improvements across multiple measures Data from the Phase 1 and Phase 2 trials of AVR-RD-01 support potential long-term engraftment and durable, endogenous production of...

Analyst and investor event to be webcast on Monday, Feb. 10, 2020, at 7:00 p.m. ET AVROBIO , Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company will provide clinical data...